HOOKIPA PHARMA INC (HOOK) Stock Analyst Ratings
USA - NASDAQ:HOOK - US43906K2096 - Common Stock
0.8403 USD
-0.06 (-6.92%)
0.83 USD
-0.01 (-1.23%)
ChartMill assigns a Buy % Consensus number of 46% to HOOK. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 29.07. This target is 3359.48% above the current price.
HOOK was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about HOOK.
In the previous month the buy percentage consensus was at a similar level.
HOOK was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-01-10 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-12-20 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2024-11-21 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-11-15 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-08-09 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-07-26 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-06-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-21 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-04-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-25 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-03-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-01-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-09-27 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-09-06 | Truist Securities | Reiterate | Buy -> Buy |
| 2023-08-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-30 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-06-05 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-05-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-20 | Truist Securities | Maintains | Buy |
| 2023-03-16 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-12-02 | B of A Securities | Downgrade | Buy -> Underperform |
| 2022-11-15 | RBC Capital | Maintains | Outperform |
| 2022-08-23 | Truist Securities | Maintains | Buy |
| 2022-08-11 | SVB Leerink | Maintains | Outperform |
| 2022-02-17 | HC Wainwright & Co. | Maintains | Buy |
| 2022-02-16 | SVB Leerink | Maintains | Outperform |
| 2021-11-12 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-11-11 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-10 | JMP Securities | Maintains | Market Outperform |
| 2021-11-10 | RBC Capital | Maintains | Outperform |
HOOKIPA PHARMA INC / HOOK FAQ
What is the average price target for HOOKIPA PHARMA INC (HOOK) stock?
7 analysts have analysed HOOK and the average price target is 29.07 USD. This implies a price increase of 3359.48% is expected in the next year compared to the current price of 0.8403.
Can you provide the consensus rating for HOOKIPA PHARMA INC stock?
The consensus rating for HOOKIPA PHARMA INC (HOOK) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
How many analysts have analysed HOOKIPA PHARMA INC (HOOK)?
The number of analysts covering HOOKIPA PHARMA INC (HOOK) is 7.